Stratec SE/€SBS

1D1W1MYTD1Y5YMAX

About Stratec SE

STRATEC SE, headquartered in Birkenfeld, Germany, specializes in designing and manufacturing fully automated analyzer systems, software, and smart consumables for the in-vitro diagnostics and life sciences sectors. Founded in 1979, the company operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on automated analyzer systems for clinical diagnostics and biotechnology clients; the Diatron segment offers systems and consumables for low-throughput hematology and clinical chemistry applications; and the Smart Consumables segment develops polymer-based consumables for diagnostics and medical applications. STRATEC primarily serves as an original equipment manufacturer (OEM), collaborating with diagnostic companies to develop products marketed under their brands. The company's global presence includes facilities in Switzerland, the United States, Romania, Hungary, Austria, and China. Its strategic positioning is reinforced by long-term partnerships with leading in-vitro diagnostics companies and a comprehensive technology portfolio that spans the entire value chain, from design and development to regulatory approval and production. (,)
Ticker
€SBS
Sector
Health
Primary listing
XETRA
Employees
1,383
Headquarters
Birkenfeld, Germany
Website
www.stratec.com

Stratec SE Metrics

BasicAdvanced
€277M
-
-€0.03
0.81
€0.60
2.58%

Bulls say / Bears say

The Q2 2026 recovery was substantial: constant-currency sales grew 2.4% year over year, adjusted EBIT increased 125.3%, and the adjusted EBIT margin expanded to 11.9% from 5.4%. (STRATEC)
Analyzer Systems sales rose 15.4% on a constant-currency basis in H1 2026, while demand for lifecycle-management projects and cybersecurity services remained high, supporting recurring customer engagement beyond initial system placements. (STRATEC)
STRATEC confirmed 2026 guidance for medium- to high-single-digit constant-currency sales growth and has outlined a potentially stronger multiyear trajectory, targeting 6%–8% sales CAGR through 2028, 10%–12% in 2029–2030, and adjusted EBIT margins of at least 13% by 2028 and 15% by 2030. (STRATEC)
H1 2026 sales fell 3.3% on a constant-currency basis, while adjusted net income declined 17.4% and adjusted EPS fell 17.1% year over year, showing that the recovery has not yet translated into stronger bottom-line performance. (STRATEC)
Profitability remains below prior levels: FY2025 adjusted EBIT margin dropped to 10.0% from 13.0%, adjusted EBITDA fell 17.4%, and the company recorded impairments tied chiefly to a delayed Diatron product launch and lower sales potential. (STRATEC)
Execution and forecasting risk is elevated because STRATEC expects most 2026 growth to come from very strong year-end volumes, while customer order decisions remain volatile; rising input costs and geopolitical factors are also expected to offset some scale benefits. (STRATEC Annual Report 2025)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.